drugset
drugset / Trial / NCT05100186

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

NCT05100186 ↗

Phase 4 Unknown 50 enrolled Joseph Kavanagh, MD
RandomizedSingle-groupOpen-labelTreatment

Summary

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.

Timeline

Start
2021-11-01
Primary completion
2021-12-31
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other

Indications

cataract